Camargo

NOVEMBER 29, 2021

Monoclonal antibodies (mAbs). They may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Blood and blood components. Allergenics.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

JULY 25, 2022

AstraZeneca and Daiichi Sankyo have received Priority Review for their supplemental Biologics License Application (sBLA) from the US Food and Drug Administration (FDA) of antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), to treat unresectable or metastatic HER2-low breast cancer in adults.

HR 130

HR Hormones Clinical Trials Clinical Trials 130

pharmaphorum

AUGUST 15, 2022

At this year’s ASCO congress, the Trop2-targeting antibody-drug conjugate (ADC) was found to improve progression-free survival significantly in in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment.

HR 90

HR Hormones Sales Antibody 90

pharmaphorum

DECEMBER 9, 2022

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (SABCS) suggest they may see success with a second.

HR 98

HR Antibody Hormones Drugs 98

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The results still require further validation, including experimental and clinical evaluation.

Research 98

Research Hormones Protein Regulation 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

DECEMBER 12, 2022

Along with data from its antibody-drug conjugates and oral selective oestrogen receptor degrader (SERD) camizestrant reported earlier, AZ presented results of the CAPItello trial of AKT inhibitor capivasertib in combination with injectable SERD Faslodex (fulvestrant) in hormone receptor positive, HER2-negative advanced breast cancer.

HR 105

HR Hormones Trials Drugs 105

Pharmaceutical Technology

FEBRUARY 23, 2023

Adlai Nortye utilizes PAINT-2D and ANEAT-Id platform technologies to identify and develop immunotherapies and antibodies. It is also evaluating AN1004 to treat human epidermal growth factor receptor-2-negative metastatic breast cancer; AN4005 against advanced tumors; AN3025 and AN6025 for solid tumors.

Hormones 130

Hormones Development Drugs Clinical Trials 130

pharmaphorum

NOVEMBER 6, 2020

Its lead candidate in clinical development is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is being tested in a phase 1 and a phase 2 clinical trial for patients with blood cancer and solid tumours, respectively. Patients in that trial had been heavily pretreated and had failed to respond to other anticancer drugs.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Trop-2 is highly expressed across multiple cancer types, with expression detected in more than 90% of breast cancers.

HR 162

HR Marketing Hormones FDA Approval 162

pharmaphorum

JULY 14, 2022

The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use.

Drugs 104

Drugs Hormones Genome Genomics 104

pharmaphorum

FEBRUARY 21, 2022

” The antibody-drug conjugate is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the DESTINY-Breast03 study looks set to expand its use into second-line treatment in breast cancer. AZ paid a hefty $1.4

Trials 132

Trials Sales Hormones Drugs 132

pharmaphorum

AUGUST 3, 2022

Cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for lymphoma and leukaemia together brought in $368 million, up 68%, while antibody drug conjugate Trodelvy (sacituzumab govitecan) rose 79% to $159 million thanks to increased uptake in triple-negative breast cancer.

Sales 105

Sales Hormones Drugs Antibody 105

Pharma Packaging Solutions

JUNE 30, 2023

Whole blood, organ and tissue transplants, breast milk, antibodies for passive immunity, fecal microbiota, human reproductive cells, and stem-cell therapy are all examples of this type of biologic.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

pharmaphorum

APRIL 25, 2022

The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice of endocrine therapy for previously-treated hormone receptor (HR)-positive, HER2-negative breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). Diagnostic led the charge, rising 24% to CHF 5.3

Trials 69

Trials Hormones HR Sales 69

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market namely Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors Amgens MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 hormone) (..)

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

XTalks

NOVEMBER 5, 2024

SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Septerna’s thyroid-stimulating hormone receptor (TSHR) modulators offer a potentially disease-modifying oral treatment. Phase I trials are underway, with data expected in mid-2025. million patients in the US.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market — namely Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors — Amgen’s MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 (..)

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Pharmaceutical Technology

FEBRUARY 18, 2023

It was also under development for the treatment of diabetic nephropathy associated with chronic kidney disease, pediatric nephrotic syndrome, metastatic hormone-refractory prostate cancer, hypertension, diabetic neuropathic pain and ovarian cancer Chinook Therapeutics Overview Chinook Therapeutics, Inc (Chinook).,

Hormones 100

Hormones Development Production Clinical Trials 100

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. Trodelvy is a Targeted Therapy Trodelvy is a Trop -2 directed antibody-drug conjugate therapy.

HR 52

HR Hormones FDA Approval Antibody 52

XTalks

MARCH 29, 2021

Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. They also believe caffeine could potentially disrupt fetal stress hormones, putting infants at risk for rapid weight gain after birth and for chronic conditions such as obesity, heart disease and diabetes later on in life.

Genotype 98

Genotype Allergies Hormones Research 98

The Pharma Data

JUNE 26, 2021

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis. Harnessing the power of antibodies to fight bone metastasis. “We feel our strategy is a real game changer.” Science Advances, 2021.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. However, the similarity between the two proteins is not great enough for anti-spike antibodies to cross-react with placental syncytin-1.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. NGM120 is a first-in-class antagonistic antibody, which binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15).

Marketing 94

Marketing Pharma Companies Development Hormones 94

Roots Analysis

OCTOBER 24, 2023

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. Antibody-Drug Conjugates: ADCs are monoclonal antibodies (mAbs) attached to surface antigens by chemical or a liable linker.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

pharmaphorum

AUGUST 8, 2022

It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug.

HR 52

HR Hormones Sales Antibody 52

Roots Analysis

MARCH 21, 2022

There has been a significant increase in the number of biologics, specifically the new generation molecules, such as monoclonal antibodies, in the late-stage clinical studies ( phase II / phase III ). This can be attributed to their relatively more efficient and patient friendly mode of drug delivery. Our Social Media Platform. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52

pharmaphorum

DECEMBER 23, 2020

NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. This is a rare disease that affects the kidney but is caused by overproduction of antibodies produced in the lining of the small intestine, for which there are no approved medications.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

The Pharma Data

JANUARY 7, 2021

He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific. To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. billion acquisition of Synthorx. Dupixent is currently approved in the U.S.

Protein 52

Protein Antibody Genetics Gene Therapy 52

The Pharma Data

AUGUST 17, 2021

About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. Immune-Mediated Pneumonitis.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

FEBRUARY 21, 2022

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo. 4 Currently, chemotherapy remains the only treatment option both for patients with HR-positive tumours following progression on endocrine (hormone) therapy, and for those who are HR-negative.5.

HR 52

HR Trials Hormones Antibody 52

XTalks

MARCH 22, 2021

The biotech acquisition deal includes Five Prime’s prime asset bemarituzumab, which is a first-in-class anti-FGFR2b antibody. The antibody accrued promising data in a randomized, placebo-controlled Phase II study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer, and is now being prepared for Phase III trials.

Life Science 110

Life Science Development Marketing Gene Expression 110

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52

pharmaphorum

JULY 19, 2022

Merck said the LYNK-003 rial of Lynparza (olaparib) given as either a monotherapy or in combination with Roche’s CD20-targeting antibody Avastin (bevacizumab) in advanced colorectal cancer has been halted, as a look at the unblinded data showed little chance of a positive result.

Trials 52

Trials Hormones FDA Approval Drugs 52